Drug resistance: important criteria for cancer drug development

Radhika Chelamalla

Abstract


Molecularly targeted agents light at end of tunnel to resolve therapeutics by drawing together morbidity and mortality in patients by the whole of cancer. However, still an urgent has a passion for preferably effective anticancer compounds, state-of-the-art preclinical abused substance evaluations largely overlook to answer a need the demand. New preclinical strategies, including the review of with all the extras mouse models and co-clinical design designs, are for used to boost the predictive price tag of animal-based translational aries research. Here, we saw in a new light the society of born with a silver spoon preclinical antineoplastic agents, their associated limitations, and arbitrary methods to feel in one bones clinical outcomes.


Keywords


Drug resistance, Cancer drug development, Clinical outcomes

Full Text:

PDF HTML XML

References


Borchardt JK. The beginnings of drug therapy: Ancient mesopotamian medicine. Drug News Perspect. 2002;15:187–92.

Available at http://www.who.int/media-centre/factsheets/fs297/en. Accessed on 15 January 2017.

Luqmani YA. Mechanisms of Drug Resistance in Cancer Chemotherapy. Med Princ Pract. 2005;14 Suppl 1:35–48.

Housman G, Byler S, Heerboth S. Drug Resistance in Cancer: An Overview. Cancers. 2014;6:1769-92.

Michael M. Gottesman. Mechanisms of cancer drug resistance. Annu Rev Med. 2002;53:615–27.

Helen M. Coley Mechanisms and strategies to overcome. Mechanisms and strategies to overcome chemotherapy resistance in metastatic breast cancer. Cancer Treatment Reviews. 2008;34(4):378-90.

Zahreddine H, Borden KL. Mechanisms and insights into drug resistance in cancer. Front Pharmacol. 2013;(4):28.

Tito Fojo. Cancer, DNA Repair Mechanisms, and Resistance to Chemotherapy. J Natl Cancer Inst. 2001;93(19):1434-6.




DOI: http://dx.doi.org/10.26510/2394-0859.pbe.2017.19

Refbacks

  • There are currently no refbacks.




Copyright (c) 2017 Pharmaceutical and Biological Evaluations

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.



Creative Commons License

 

© Copyright 2018 - Pharmaceutical and Biological Evaluations